Semaglutide's Kidney Benefit Confirmed for All Diabetes Patients, With or Without Heart Disease
A June 2026 JACC subgroup analysis of the FLOW trial confirmed that semaglutide reduces major kidney events and death consistently across cardiovascular subgroups in type 2 diabetes and chronic kidney disease.
Dr. Helena Vasquez, MD Jul 31, 2026 4 min read